Paper23429381
Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
Mira JA and 15 others. Clin Infect Dis, 2013. Cited by 69 papers, by iCite.
Cite this record
ConductScience Library. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Papers, record 23429381. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23429381
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| HIV Infections | Major topic |
| Hepatitis C | Major topic |
| Interferon-alpha | Major topic |
| Liver Cirrhosis | Major topic |
| Polyethylene Glycols | Major topic |
| Ribavirin | Major topic |
| Adult | |
| Female | |
| Hepacivirus | |
| Humans | |
| Kaplan-Meier Estimate | |
| Liver Failure | |
| Male | |
| Middle Aged | |
| Multivariate Analysis | |
| Prospective Studies | |
| Recombinant Proteins |
Source PubMed
Cited by36
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 69 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39970137 | Influence of Cellular Aging on Liver Stiffness in Patients With Hepatitis C Virus Achieving Sustained Viral Response. | J Infect Dis | 2025 | https://conductscience.org/library/papers/39970137 | PubMed |
| 36526593 | Evaluation of treatment access and scope of a multistate hepatitis C virus Extension for Community Healthcare Outcomes telehealth service in the US Indian Health System, 2017-2021. | J Rural Health | 2023 | https://conductscience.org/library/papers/36526593 | PubMed |
| 35646260 | Revolution in the diagnosis and management of hepatitis C virus infection in current era. | World J Hepatol | 2022 | https://conductscience.org/library/papers/35646260 | PubMed |
| 35126840 | Hepatitis C: Problems to extinction and residual hepatic and extrahepatic lesions after sustained virological response. | World J Hepatol | 2022 | https://conductscience.org/library/papers/35126840 | PubMed |
| 35030279 | HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis. | Hepatology | 2022 | https://conductscience.org/library/papers/35030279 | PubMed |
| 33822285 | Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis. | Eur J Clin Microbiol Infect Dis | 2021 | https://conductscience.org/library/papers/33822285 | PubMed |
| 31434968 | Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR. | Sci Rep | 2019 | https://conductscience.org/library/papers/31434968 | PubMed |
| 30682180 | Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study. | PLoS One | 2019 | https://conductscience.org/library/papers/30682180 | PubMed |
| 30215672 | Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/30215672 | PubMed |
| 30209336 | Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality. | Sci Rep | 2018 | https://conductscience.org/library/papers/30209336 | PubMed |
| 30075765 | Glomerular filtration rate change during chronic hepatitis C treatment with Sofosbuvir/Ledipasvir in HCV/HIV Coinfected patients treated with Tenofovir and a boosted protease inhibitor: an observational prospective study. | BMC Infect Dis | 2018 | https://conductscience.org/library/papers/30075765 | PubMed |
| 29467555 | Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort. | World J Gastroenterol | 2018 | https://conductscience.org/library/papers/29467555 | PubMed |
| 29299684 | Treatment of hepatitis C in special populations. | J Gastroenterol | 2018 | https://conductscience.org/library/papers/29299684 | PubMed |
| 29098647 | Current and future challenges in HCV: insights from an Italian experts panel. | Infection | 2018 | https://conductscience.org/library/papers/29098647 | PubMed |
| 28294492 | High prevalence of willingness to use direct-acting antiviral-based regimens for hepatitis C virus (HCV) infection among HIV/HCV coinfected people who use drugs. | HIV Med | 2017 | https://conductscience.org/library/papers/28294492 | PubMed |
| 28210927 | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. | Hepatol Int | 2017 | https://conductscience.org/library/papers/28210927 | PubMed |
| 28160269 | Infections in Cancer Patients with Solid Tumors: A Review. | Infect Dis Ther | 2017 | https://conductscience.org/library/papers/28160269 | PubMed |
| 27787664 | Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy. | Eur J Clin Microbiol Infect Dis | 2017 | https://conductscience.org/library/papers/27787664 | PubMed |
| 27272121 | Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response. | Eur J Clin Microbiol Infect Dis | 2016 | https://conductscience.org/library/papers/27272121 | PubMed |
| 27241060 | HLA-B18 as a risk factor of short-term progression to severe liver fibrosis in HIV/HCV co-infected patients with absent or minimal fibrosis: implications for timing of therapy. | Pharmacogenomics J | 2017 | https://conductscience.org/library/papers/27241060 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23429381
GET https://conductscience.org/api/papers/v1/23429381/cited_by?page=2